Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert-v1
    X

    Find Oncology Drugs in Phase II Clinical Development in CHINA

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              HUYA Bioscience International

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Duphat

              Participation Not Confirmed

              Request a Meeting Now

              HUYA Bioscience International Appoints Meiji Seika Pharma as Exclusive Distributor For HBI-8000 in Japan and Other Asian Countries

              Contact the Supplier

              Lead Product(s): Tucidinostat

              Therapeutic Area: Oncology

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Meiji Seika Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 08, 2020

              Details:

              HUYABIO will complete the development of HBI-8000 for PTCL and ATL in Japan for commercialization by Meiji who will hold exclusive sales and marketing rights.

              I-Mab Biopharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CHINA China

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Duphat

              Participation Not Confirmed

              Request a Meeting Now

              I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Phase 2 Study of TJ202/MOR202 in Multiple Myeloma in Mainland China

              Contact the Supplier

              Lead Product(s): MOR202,Lenalidomide,Dexamethasone

              Therapeutic Area: Oncology

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 03, 2020

              Details:

              I-Mab initiated two registrational trials with TJ202/MOR202 in relapsed or refractory MM in Taiwan in early 2019 &expanded these trials into mainland China in late 2019, after receiving IND clearance from the (NMPA)

              PharmaCompass__DigitalAd